Original Query: ALL
Previous Study | Return to List | Next Study

A Comparison of Seroquel vs. Risperidone in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00034905
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : January 4, 2013
Information provided by:

Brief Summary:
The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: quetiapine fumarate vs risperidone Phase 4

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Study Start Date : July 2001
Primary Completion Date : September 2002
Study Completion Date : September 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Male / Female, 18-65 years old
  • Schizophrenia (as per DSM IV)

Exclusion Criteria

  • Concurrent use of psychotropic medication
  • Does not fulfill moderately ill on CGI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00034905

  Show 64 Study Locations
Sponsors and Collaborators
AstraZeneca Identifier: NCT00034905     History of Changes
Other Study ID Numbers: 5077US/0043
First Posted: May 3, 2002    Key Record Dates
Last Update Posted: January 4, 2013
Last Verified: January 2013

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Quetiapine Fumarate
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents